Abou-Donia M and Lapadula DM. Mechanisms of organophosphorus ester-induced delayed neurotoxi-city: Type I and type II. Annu Rev Pharmacol Toxicol 1990;30:405-440.
Evoli A, Batocchi AP, and Tonali P. A practical guide to the recognition and management of myasthenia gravis. Drugs 1996;52:662-670.
Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galanthamine. Clin Ther 2001;23:A13-A24.
Felder C. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J 1995;9:619-625.
Hoyng PF and van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;411-34.
Millard CB and Broomfield CA. Anticholinesterases: Medical applications of neurochemical principles. J Neurochem 1995 64:1909-1918.
Schneider LS. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med 2001;17:337-358.
Treatment of nerve gas poisoning. Med Lett 1995;37:43-44.
Was this article helpful?
The comprehensive new ebook All About Alzheimers puts everything into perspective. Youll gain insight and awareness into the disease. Learn how to maintain the patients emotional health. Discover tactics you can use to deal with constant life changes. Find out how counselors can help, and when they should intervene. Learn safety precautions that can protect you, your family and your loved one. All About Alzheimers will truly empower you.